| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c22c6d06e5563aee18cc3c610cfa6180 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G83-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G83-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate |
2001-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47aaabde55a634159d1b09c8cbfe7250
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9ca7564386b79cc99d5293e6d1fe34d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a902ce997c79d580780308d195018df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9fcd3b19f7baaa32899fa92b70b07bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3519964771e88f4bea25920a16adb058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4c45af64b6b4734a4ba51e00f785df4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6984cdfc3914a4369d7779a2bd6cc53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdd7ca58479cd0d45823d5a69ff13b22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf5b0a271651e6fe7f60e0b7fd24da8 |
| publicationDate |
2003-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2427539-A1 |
| titleOfInvention |
Method for obtaining antigenic structures enhancing specific cross reactivity |
| abstract |
The invention relates to a method for obtaining high cross reactivity antigenic structures that are capable of enhancing an immune response to peptidic antigens administered systemically and/or mucosally and to the chemical structures obtained with said method and the formulations obtained from said structures and their utilization. The method describes the obtention of new dendrimeric structures from the selection and synthesis of dendrimers that are subsequently coupled to carrier molecules. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens of this type can be introduced, a synergistic effect taking place between these components in relation to the cross reactivity and the immunogenicity of the response obtained. The preparation may also contain stabilizers and preserving agents. The resulting antigenic structures can be used in the pharmaceutical industry as vaccine formulations for human and veterinary use and as part of diagnostic systems. |
| priorityDate |
2000-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |